Cancer immunotherapy requires ICB, such as CTLA-4 and monoclonal antibodies against PD-1 or PD-L1, which restore the function of cytotoxic effector CD8+ T cells and kill cancer cells, leading to tumor suppression and a paradigm shift in cancer treatment for many cancer types. This evidence concerns the gene CD8A and cancer.